Although several S1P1 modulators are either approved in multiple sclerosis (e.g. fingolimod, siponimod and ozanimod) or are in clinical development for immuno-inflammatory disorders, they were all developed as S1P1 functional antagonists that cause peripheral blood lymphopenia through S1P1 desensitization. This evidence concerns the gene S1PR1 and lymphopenia.